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Cochrane Review Summary for Cancer Nursing:  
Drug Therapy for Cancer-related Fatigue 
 
Background  
Cancer-related fatigue (CRF) is one of the most debilitating symptoms in 
patients with cancer. It is prevalent at the time of diagnosis, during and after 
antineoplastic treatment, and in patients with advanced disease.  The multi-
factorial and complex nature of CRF makes it challenging for health 
professionals to identify a clear underlying mechanism and manage this 
symptom effectively. Often, the management plan for CRF (whether 
pharmacological or non-pharmacological) can be further complicated by the 
co-existence of other symptoms. This systematic review (1) is therefore 
important in informing health professionals on the effectiveness of 
pharmacological management for CRF.   
 
 
Objective/s  
The objectives of this review were to (i) assess the effectiveness and adverse 
events associated with drugs used for CRF in patients with cancer, compared 
with standard care or non-pharmacological interventions and (ii) to determine 
optimal dose and duration of drug therapy(ies). Only randomised controlled 
trials (RCTs) were included in this review. 
 
 
Intervention/Methods 
The Cochrane review included 31 RCTs. In total, 7104 participants older than 
18 years were included in the review. Patients included in these trials were at 
different point of the cancer treatment spectrum. All included trials compared 
a drug therapy with placebo, standard care or an alternative non-
pharmacological treatment for CRF. All included trials included differences in 
fatigue between intervention group and controls as the outcomes of interest, 
using patient self-reported measures or other validated research instruments. 
The methodological soundness varied across all included trials. The trials 
assessed the effectiveness of four classes of drugs for improving CRF; 
psychostimulants, haemopoietic growth factors, anti-depressants and 
progestational steroids.  
 
 
Results 
Psychostimulants 
Data from a meta-analysis of five studies (N=410) showed that, overall, 
psychostimulants (methylphenidate and dexamphetamine) had statistically 
significant effects in reducing CRF compared to placebo. The overall effect Z 
score=2.83 (p=0.005, Standard Mean Difference [SMD]=-0.28, 95% 
Confidence Intervals [CI]: -0.48 to -0.09), with I² statistics of 0%, indicating no 
important heterogeneity between the trials. The dosages of methylphenidate 
used the four included trials varied (from 5mg up to 20mg every 24 hours).  
 
Haemopoietic growth factors 
In this review, the effects of two haemopoietic growth factors (erythropoietin 
and darbopoietin) were analysed separately. Data from a meta-analysis of 11 
studies (N=2348) showed that, overall, erythropoietin had statistically 
significant effects in reducing CRF compared to no intervention. All these 
trials recruited anaemic cancer patients with a Haemoglobin level <12g/dl). 
The overall effect Z score=7.31 (p<0.00001, SMD=-0.36, 95% CI: -0.46 to -
0.26), with an I² statistics of 20%. The heterogeneity was probably due to 
study quality and lack of blinding in allocation in some of the included trials. 
For darbopoietin, data from a meta-analysis of four studies (N=964) showed 
that, overall, darbopoietin had a small but statistically significant effect in 
reducing CRF compared to no intervention. The overall effect Z score=1.96 
(p=0.05, SMD=-0.13, 95%CI: -0.27 to 0.00), with I² statistics of 0%, indicating 
no important heterogeneity between the trials.  
 
Anti-depressants 
Two trials assessed the effects of paroxetine in reducing CRF. Data from the 
meta-analysis of the two trials (n=643) showed that, overall, paroxetine was 
not superior to placebo in reducing CRF (p=0.29). 
 
Progestational steroids 
Four trials assessed the effects of mesgestrol acetate or 
medroxyprogesterone acetate. Data from the meta-analysis of the four trials 
(n=587) indicated no difference between progestational steroids and placebo 
for reducing CRF. There was significant heterogeneity between the trials 
(I²=98%). 
 
Adverse effects 
The majority of trials included in this review had minimal reported adverse 
events compared to the control/placebo groups for all four classes of drugs. 
The review did not report on the specific types of adverse events. 
 
 
Conclusions 
There is now evidence of some benefits in using methylphenidate for treating 
CRF compared to placebo. Although haemopoietic growth factors had 
significant effects in treating fatigue in anaemic cancer patients compared to 
no intervention, and minimal adverse events were reported it should be noted 
that evidence from another systematic review (2) suggests there are safety 
concerns and side effects associated with these drugs. Anti-depressants and 
progestational steroids were not superior to placebo. 
 
 
Implications for Practice 
- For patients with CRF, the review author recommended that 
methylphenidate may be considered for use in a dose of 10 to 20mg 
per day depending on response. There were minimal serious adverse 
effects, however, contra-indications to this drug should be considered 
before use. 
- Erythropoietin and darbopoietin can no longer be recommended for 
treating CRF due the adverse events associated with these drugs. 
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